Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

"EFFICACY, IMMUNOGENICITY, AND SAFETY STUDY OF CLOSTRIDIUM DIFFICLE TOXOIS VACCINE IN SUBJECTS AT RISK FOR C. DIFFICILE INFECTION."

Intervention/treatment:
CLOSTRIDIUM DIFFICILE TOXOID VACCINE
Medical condition:
CLOSTRIDIUM DIFFICILE INFECTION
Protocol code:
H-030-014
Control number:
165777
Status:
Closed
Approved:
July 24, 2013
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT01887912
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
50 Years and older
Accepts healthy volunteers: Yes

Contacts and locations

Contact
Name
Medical Director
Organization
Sanofi Pasteur
Phone:
800-633-1610
Extension 1#
Sponsor
SANOFI PASTEUR INC

Locations

British Columbia

New Westminster, British Columbia, V3L 3W7
Investigational Site 156
Surrey, British Columbia, V3V 1Z2
Investigational Site 158
Vancouver, British Columbia, V5Z IM9

Manitoba

Investigational Site 158
Winnipeg, Manitoba, R3A IR9

Nova Scotia

Investigational Site 156
Halifax, Nova Scotia, B3K 6R8
Investigational Site 163
Truro, Nova Scotia, B2N 1L2

Ontario

Guelph, Ontario, N1H 1B1
Investigational Site 161
Toronto, Ontario, M5G 1X5

Quebec

Investigational Site 151
Montreal, Quebec, H3T 1E2
Investigational Site 151
Sherbrooke, Quebec, J1H5N4
Investigational Site 152
Pierrefonds, Quebec, H9H 4Y6
Investigational Site 152
Québec, Quebec, G1E 7G9
Investigational Site 161
Trois-Rivières, Quebec, G8Z 3R9

Results

See the results from the trial NCT01887912. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?